Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Credo Diagnostics Combo Influenza, COVID-19 Test Receives CE-IVD Mark

Credo Diagnostics Combo Influenza, COVID-19 Test Receives CE-IVD Mark

Oct 30, 2020
|
staff reporter

NEW YORK – Credo Diagnostics Biomedical announced Friday its combination VitaPCR Influenza A&B/SARS-CoV-2 test received CE-IVD marking. 

The point-of-care RT-PCR test delivers results from one nasopharyngeal sample in 20 minutes and can be used on the firm's VitaPCR instrument. The platform can perform 24 runs per day with one sample per run and doesn't need "highly trained personnel," Credo said in a presentation on the test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

European Regulators Begin Review of Sputnik V

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Irish Funding Agency Seeks Boost

Science reports that Science Foundation Ireland is seeking annual budget increases.

Lower Fees Sought

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

Nature Papers Examine Peregrine Falcon Migration Patterns, Tool to Search Single-Cell Data

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

  2. Qiagen MDx Sample Processing Platform Garners CE-IVD Mark

  3. FDA Grants Emergency Use Authorization for University of Illinois Coronavirus PCR Test

  4. FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.